1217 related articles for article (PubMed ID: 12970748)
1. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
2. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A
Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767
[TBL] [Abstract][Full Text] [Related]
3. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Wellstein A; Morgan E; Czubayko F; List HJ; Reiter R; Martin MB; Stoica A
Oncogene; 2003 Apr; 22(14):2073-87. PubMed ID: 12687010
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
5. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
6. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I.
Martin MB; Franke TF; Stoica GE; Chambon P; Katzenellenbogen BS; Stoica BA; McLemore MS; Olivo SE; Stoica A
Endocrinology; 2000 Dec; 141(12):4503-11. PubMed ID: 11108261
[TBL] [Abstract][Full Text] [Related]
7. The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway.
Lehnes K; Winder AD; Alfonso C; Kasid N; Simoneaux M; Summe H; Morgan E; Iann MC; Duncan J; Eagan M; Tavaluc R; Evans CH; Russell R; Wang A; Hu F; Stoica A
Endocrinology; 2007 Mar; 148(3):1171-80. PubMed ID: 17138652
[TBL] [Abstract][Full Text] [Related]
8. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
Felekkis KN; Narsimhan RP; Near R; Castro AF; Zheng Y; Quilliam LA; Lerner A
Mol Cancer Res; 2005 Jan; 3(1):32-41. PubMed ID: 15671247
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts.
Yamane K; Ihn H; Tamaki K
Arthritis Rheum; 2003 Jun; 48(6):1652-66. PubMed ID: 12794834
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
[TBL] [Abstract][Full Text] [Related]
12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
13. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines.
Kimura A; Ohmichi M; Kawagoe J; Kyo S; Mabuchi S; Takahashi T; Ohshima C; Arimoto-Ishida E; Nishio Y; Inoue M; Kurachi H; Tasaka K; Murata Y
Oncogene; 2004 Jun; 23(26):4505-15. PubMed ID: 15048073
[TBL] [Abstract][Full Text] [Related]
14. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
Gaben AM; Saucier C; Bedin M; Redeuilh G; Mester J
Mol Endocrinol; 2004 Nov; 18(11):2700-13. PubMed ID: 15297603
[TBL] [Abstract][Full Text] [Related]
15. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
16. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Hermanto U; Zong CS; Wang LH
Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727
[TBL] [Abstract][Full Text] [Related]
17. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells.
Duan R; Xie W; Li X; McDougal A; Safe S
Biochem Biophys Res Commun; 2002 Jun; 294(2):384-94. PubMed ID: 12051724
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
[TBL] [Abstract][Full Text] [Related]
19. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
Söderlund K; Pérez-Tenorio G; Stål O
Int J Oncol; 2005 Jan; 26(1):25-32. PubMed ID: 15586221
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
